The acamprosate group demonstrated significantly superior efficacy versus the placebo group on the primary endpoint : the proportion maintaining complete abstinence in the acamprosate group was 47.2 % ( 77/163 subjects ) , compared with 36.0 % ( 59/164 subjects ) in the placebo group ( P = .039 ) .